Dipòsit Digital de Documents de la UAB 12 registres trobats  1 - 10següent  anar al registre: La cerca s'ha fet en 0.00 segons. 
1.
16 p, 1.2 MB Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial / Thaçi, Diamant (University of Luebeck) ; Strober, Bruce (Yale University) ; Gordon, Kenneth B. (Medical College of Wisconsin) ; Foley, Peter (The University of Melbourne) ; Gooderham, Melinda (Queen's University and Probity Medical Research) ; Morita, Akimichi (Nagoya City University) ; Papp, Kim A. (Clinical Research and Probity Medical Research) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Menter, M. Alan (Baylor University Medical Center) ; Colombo, Matthew J. (Bristol Myers Squibb) ; Elbez, Yedid (Bristol Myers Squibb) ; Kisa, Renata M. (Bristol Myers Squibb) ; Ye, June (Bristol Myers Squibb) ; Napoli, Andrew A. (Bristol Myers Squibb) ; Wei, Lan (Bristol Myers Squibb) ; Banerjee, Subhashis (Bristol Myers Squibb) ; Merola, Joseph F. (Harvard Medical School) ; Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ; Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510  
2.
1 p, 118.3 KB Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79  
3.
9 p, 713.2 KB Efficacy of Dupilumab in Atopic Dermatitis : The Patient's Perspective / de Bruin-Weller, Marjolein (University Medical Center) ; Merola, Joseph F. (Harvard Medical School) ; Hong, Chih-ho (Probity Medical Research) ; Baldrich, Esther Serra (Institut d'Investigació Biomèdica Sant Pau) ; Ettler, Karel (University Hospital Hradec Kralove (República Txeca)) ; Sierka, Debra (Sanofi Genzyme, Cambridge) ; Delevry, Dimittri (Regeneron Pharmaceuticals. Inc) ; Chen, Zhen (Regeneron Pharmaceuticals. Inc) ; Rossi, Ana Beatris (Sanofi Genzyme, Cambridge) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). [...]
2021 - 10.1007/s13555-021-00621-w
Dermatology and Therapy, Vol. 11 (november 2021) , p. 2123-2131  
4.
16 p, 894.7 KB Evolution of Patient Perceptions of Psoriatic Disease : Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey / Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ; Langley, Richard G. (Dalhousie University) ; Paul, Carle (Paul Sabatier University) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; van de Kerkhof, Peter (Radboud University Medical Center) ; Wu, Hsiuan-Lin (Amgen Inc) ; Richter, Sven (Amgen Inc) ; Jardon, Shauna (Amgen Inc) ; Gisondi, Paolo (University Hospital of Verona (Itàlia)) ; Universitat Autònoma de Barcelona
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists. [...]
2021 - 10.1007/s13555-021-00635-4
Dermatology and Therapy, october 2021, p. 1-16  
5.
16 p, 2.0 MB Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors / Kokolakis, Georgios (Charité-Universitätsmedizin Berlin. Clinic of Dermatology, Venereology and Allergology, Psoriasis Research and Treatment Centre) ; Vadstrup, Kasper (LEO Pharma A/S) ; Hansen, Jes B. (LEO Pharma A/S) ; Carrascosa, Jose-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Obesity, smoking, and alcohol consumption are prevalent in psoriasis patients and have been associated with increased disease severity and reduced treatment adherence and response. This post hoc analysis of pooled data from the phase 3 AMAGINE-2 and -3 trials compared the efficacy of brodalumab versus ustekinumab in psoriasis patients with aggravating and potentially treatment-confounding lifestyle risk factors. [...]
2021 - 10.1007/s13555-021-00618-5
Dermatology and Therapy, Vol. 11 (october 2021) , p. 2027-2042  
6.
14 p, 980.7 KB Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis : A Machine Learning Predictive Model / Papp, Kim A. (K Papp Clinical Research and Probity Medical Research) ; Soliman, Ahmed M. (AbbVie, Inc) ; Done, Nicolae (Analysis Group, Inc) ; Carley, Christopher (Analysis Group, Inc) ; Lemus Wirtz, Esteban (Analysis Group, Inc) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Risankizumab has demonstrated efficacy in treating moderate-to-severe psoriasis. The phase-3 IMMhance trial (NCT02672852) examined the effect of continuing versus withdrawing from risankizumab treatment on psoriasis severity, including the Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA). [...]
2021 - 10.1007/s13555-021-00550-8
Dermatology and Therapy, Vol. 11 (may 2021) , p. 1291-1304  
7.
11 p, 972.3 KB Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab / Lambert, Jo (Universitair Ziekenhuis Gent) ; Hansen, Jes Birger (LEO Pharma A/S) ; Sohrt, Anne (LEO Pharma A/S) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Targeted biological therapies for psoriasis have resulted in significant benefits, with therapeutic goals such as clear or almost clear skin accompanied by improvements in health-related quality of life (HRQoL). [...]
2021 - 10.1007/s13555-021-00545-5
Dermatology and Therapy, Vol. 11 (may 2021) , p. 1265-1275  
8.
21 p, 1000.2 KB Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis : A Network Meta-analysis / Armstrong, April W. (University of Southern California. Department of Dermatology, Keck School of Medicine) ; Soliman, Ahmed M. (AbbVie, Inc) ; Betts, Keith A. (Analysis Group, Inc) ; Wang, Yan (Analysis Group, Inc) ; Gao, Yawen (Analysis Group, Inc) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Augustin, Matthias (University Medical Center Hamburg-Eppendorf) ; Universitat Autònoma de Barcelona
The clinical benefits of biologic and oral treatments for moderate-to-severe plaque psoriasis are well-established, but efficacy outcomes can vary across therapies. Comparative efficacy analysis can be highly informative in clinical settings with multiple therapeutic options. [...]
2021 - 10.1007/s13555-021-00511-1
Dermatology and Therapy, Vol. 11 (march 2021) , p. 885-905  
9.
11 p, 532.2 KB The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis / Piquero-Casals, Jaime (Dermik. Multidisciplinary Dermatology Clinic) ; Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morgado-Carrasco, Daniel (Hospital Clínic i Provincial de Barcelona) ; Narda, Mridvika (ISDIN. Innovation and Development) ; Trullas, Carles (ISDIN. Innovation and Development) ; Granger, Corinne (ISDIN. Innovation and Development) ; Fabbrocini, Gabriella (University of Naples Federico II. Department of Clinical Medicine and Surgery) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD) is a chronic inflammatory skin disease with an estimated prevalence of 10-15% in children and 2-10% in adults. Clinically, there is notable phenotypic variability driven by a complex interaction between genetics, immune function, and the environment. [...]
2021 - 10.1007/s13555-021-00495-y
Dermatology and Therapy, Vol. 11 (february 2021) , p. 315-325  
10.
22 p, 792.5 KB Biosimilar Drugs for Psoriasis : Principles, Present, and Near Future / Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Jacobs, Ira (Pfizer Inc) ; Petersel, Danielle (Pfizer Inc) ; Strohal, Robert (Federal Academic Teaching Hospital of Feldkirch) ; Universitat Autònoma de Barcelona
Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting approximately 1-5% of the population worldwide) and is associated with significant morbidity. The introduction of biologic therapies has improved the management of this disease. [...]
2018 - 10.1007/s13555-018-0230-9
Dermatology and Therapy, Vol. 8 (march 2018) , p. 173-194  

Dipòsit Digital de Documents de la UAB : 12 registres trobats   1 - 10següent  anar al registre:
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.